Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
1-A
1-A POS
1-A-W
1-A/A
1-K
1-K/A
1-SA
1-SA/A
1-U
1-U/A
1-Z
1-Z-W
1-Z/A
1/A
10-12B
10-12B/A
10-12G
10-12G/A
10-D
10-D/A
10-K
10-K/A
10-K405
10-K405/A
10-KT
10-KT/A
10-Q
10-Q/A
10-QSB
10-QSB/A
10-QT
10-QT/A
10KSB
11-K
11-K/A
11-KT
13F-HR
13F-HR/A
13F-NT
13F-NT/A
13FCONP
144
144/A
15-12B
15-12B/A
15-12G
15-12G/A
15-15D
15-15D/A
15F-12B
15F-12G
15F-12G/A
15F-15D
18-K
18-K/A
19B-4E
2-E
20-F
20-F/A
20FR12B
20FR12B/A
20FR12G/A
24F-2NT
24F-2NT/A
25
25-NSE
25-NSE/A
25/A
253G1
253G2
253G3
3
3/A
305B2
305B2/A
4
4/A
40-17F1
40-17F1/A
40-17F2
40-17F2/A
40-17G
40-17G/A
40-202A
40-202A/A
40-206A
40-24B2
40-33
40-6B
40-6B/A
40-6C
40-6C/A
40-8B25
40-8F-2/A
40-APP
40-APP/A
40-F
40-F/A
40-OIP
40-OIP/A
40FR12B
40FR12B/A
424B1
424B2
424B3
424B4
424B5
424B7
424B8
424H
424H/A
425
485APOS
485B24E
485BPOS
485BXT
486APOS
486BPOS
486BXT
487
497
497AD
497J
497K
5
5/A
6-K
6-K/A
8-A12B
8-A12B/A
8-A12G
8-A12G/A
8-K
8-K/A
8-K12B
8-K12B/A
8-K12G3
8-K12G3/A
8-K15D5
8-K15D5/A
8-M
9-M
ABS-15G
ABS-15G/A
ABS-EE
ABS-EE/A
ADV-E
ADV-H-C
ADV-H-T
ADV-NR
ANNLRPT
APP NTC
APP ORDR
APP WD
APP WD/A
ARS
ARS/A
ATS-N
ATS-N/CA
ATS-N/MA
ATS-N/UA
AW
AW WD
C
C-AR
C-AR-W
C-AR/A
C-TR
C-U
C-U-W
C-W
C/A
C/A-W
CB
CB/A
CERT
CERTARCA
CERTBATS
CERTCBO
CERTNAS
CERTNYS
CERTPAC
CFPORTAL
CFPORTAL/A
CORRESP
CT ORDER
D
D/A
DEF 14A
DEF 14C
DEF13E3
DEF13E3/A
DEFA14A
DEFA14C
DEFC14A
DEFC14A
DEFC14C
DEFM14A
DEFM14C
DEFN14A
DEFR14A
DEFR14C
DEFS14A
DEFS14C
DEL AM
DFAN14A
DFRN14A
DOS/A
DSTRBRPT
DSTRBRPT/A
EFFECT
F-1
F-1/A
F-10
F-10/A
F-10EF
F-1MEF
F-3
F-3/A
F-3ASR
F-3D
F-4
F-4/A
F-6
F-6 POS
F-6/A
F-6EF
F-7
F-8 POS
F-80
F-N
F-X
F-X/A
FOCUSN
FOCUSN/A
FWP
G-405
G-FIN/A
IRANNOTICE
MA
MA-A
MA-I
MA-I/A
MA-W
MA/A
MSD
MSD/A
N-14
N-14 8C
N-14 8C/A
N-14/A
N-14MEF
N-18F1
N-1A
N-1A/A
N-2
N-2/A
N-23C-2
N-23C3A
N-23C3B
N-2MEF
N-30B-2
N-30D
N-30D/A
N-4
N-4/A
N-54A
N-54C
N-6
N-6/A
N-6F
N-8A
N-8A/A
N-8B-2/A
N-8F
N-8F NTC
N-8F ORDR
N-8F/A
N-CEN
N-CEN/A
N-CSR
N-CSR/A
N-CSRS
N-CSRS/A
N-MFP2
N-MFP2/A
N-PX
N-PX/A
N-Q
N-Q/A
NO ACT
NPORT-P
NPORT-P/A
NRSRO-CE
NRSRO-CE/A
NRSRO-UPD
NSAR-A
NSAR-A/A
NSAR-AT
NSAR-B
NSAR-B/A
NSAR-BT
NSAR-U
NSAR-U/A
NT 10-K
NT 10-K/A
NT 10-Q
NT 10-Q/A
NT 11-K
NT 20-F
NT 20-F/A
NT N-CEN
NT N-MFP2
NT NPORT-EX
NT-NCSR
NT-NCSR/A
NT-NSAR
NT-NSAR/A
NTFNCSR
NTN 10Q
POS 8C
POS AM
POS AMI
POS EX
POS462B
POSASR
PRE 14A
PRE 14C
PREC14A
PREC14C
PREM14A
PREM14C
PREN14A
PRER14A
PRER14C
PRRN14A
PX14A6G
QRTLYRPT
QUALIF
REG-NR
REGDEX
REGDEX/A
REVOKED
RW
RW WD
S-1
S-1/A
S-11
S-11/A
S-11MEF
S-1MEF
S-1MEF
S-3
S-3/A
S-3ASR
S-3D
S-3DPOS
S-3MEF
S-4
S-4 POS
S-4/A
S-4MEF
S-6
S-6/A
S-8
S-8 POS
S-B
S-B/A
SC 13D
SC 13D/A
SC 13E
SC 13E/A
SC 13E1
SC 13E1/A
SC 13E3
SC 13E3/A
SC 13E4
SC 13E4/A
SC 13G
SC 13G/A
SC 14D9
SC 14D9/A
SC 14F1
SC TO-C
SC TO-I
SC TO-I/A
SC TO-T
SC TO-T/A
SC14D9C
SD
SD/A
SDR/A
SE
SEC STAFF
SEC STAFF ACTION
SEC STAFF LETTER
SF-1/A
SF-3
SF-3/A
SUPPL
T-3
T-3/A
TA-1
TA-1/A
TA-2
TA-2/A
TA-W
UPLOAD
WDL-REQ
X-17A-5
X-17A-5/A
Tags
Inv. presentation
Quarterly results
Director comp.
Appointed director
CC transcript
ENZO BIOCHEM INC (ENZ)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
06/11/2021
8-K
Quarterly results
03/16/2021
8-K
Quarterly results
12/14/2020
8-K
Quarterly results
Docs:
"
Conference call and live webcast scheduled for today, Wednesday, December 9, 2020 at 4:30 pm
"
06/08/2020
8-K
Quarterly results
Docs:
"
Press Release of Enzo Biochem, Inc.
"
03/05/2020
8-K
Quarterly results
12/10/2019
8-K
Quarterly results
10/15/2019
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS FISCAL FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
"
06/10/2019
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS FISCAL THIRD QUARTER AND NINE MONTHS OPERATING RESULTS -------- Company Outlines Three Prong Short-Term Value Creation and Growth Strategy Intellectual Property Settlements Generate Approximately $30 Million in Cash in the Third Quarter , June 10, 2019 -- Enzo Biochem, Inc. , an integrated life sciences company focused on commercializing innovative diagnostic and therapeutics products, today reported results for the fiscal quarter and nine months ended April 30, 2019. The Company updated the market on the progress of its short-term growth and profitability initiatives designed to unlock value. Financial Results
"
03/11/2019
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS SECOND FISCAL QUARTER AND FIRST HALF 2019 RESULTS AND REPORTS PROGRESS ON ITS INVESTMENTS AND STRATEGIC GOALS , March 11, 2019 -- Enzo Biochem, Inc. , an integrated diagnostics and therapeutics company, today reported results for the fiscal quarter and first half ended January 31, 2019 along with providing more detail on its investments in the development of novel diagnostic system and centralized clinical services. Recent Developments
"
12/10/2018
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS FISCAL 2019 FIRST QUARTER RESULTS ------- Recent Reimbursement Cuts Emphasize Value of Enzo’ s Strategy
"
10/15/2018
8-K
Quarterly results
03/12/2018
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS SECOND QUARTER AND FIRST HALF RESULTS ----- Integrated Diagnostic Company Reports Higher Revenues
"
12/07/2017
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS IMPROVED FIRST QUARTER RESULTS --- Clinical Labs Posts Double Digit Revenue Increase, Sharply Higher Operating Income --- Outlook Buoyed by Successful Product Developments, Especially Women’ s Health Panel
"
09/27/2017
8-K
Quarterly results
06/08/2017
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS INCREASED REVENUES, IMPROVED OPERATING RESULTS Clinical Labs Records Sixth Straight Quarterly Revenue Gain on Growing Molecular Diagnostics Volume New York State Approvals of New Molecular Diagnostic Assays Highlight R&D Activity
",
"
Enzo Biochem Announces New York State Health Department Approval of New Women’ s Health Diagnostics Underscores Enzo’ s Growing Test Menu of High Performing Molecular Diagnostics
"
03/13/2017
8-K
Form 8-K - Current report
12/08/2016
8-K
Form 8-K - Current report
10/13/2016
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS STRONG 2016 OPERATING RESULTS -----
"
06/08/2016
8-K
Form 8-K - Current report
03/09/2016
8-K
Form 8-K - Current report
12/07/2015
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS STRONG FIRST QUARTER Execution on Corporate Strategy seen in Company’ s Results
"
10/13/2015
8-K
Quarterly results
Docs:
"
Settlement and License Agreement between Enzo Life Sciences, Inc., and Affymetrix, Inc
",
"
ENZO BIOCHEM REPORTS STRONG FOURTH QUARTER RESULTS ----- Higher Revenues and Operating Income, Plus Legal Settlements, Result in Net Income Exceeding $8 Million, or 18 Cents Per Share
",
"
Enzo Biochem Reaches $10 Million Patent Infringement Settlement with Affymetrix, Inc.
"
06/09/2015
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS THIRD QUARTER RESULTS, INCLUDING STRONG REVENUE GROWTH AT CLINICAL LABS REFLECTING INCREASING VOLUME AND GREATER MOLECULAR DIAGNOSTIC ACTIVITY
"
03/12/2015
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS FISCAL SECOND QUARTER RESULTS
"
12/09/2014
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS STRONG FISCAL FIRST QUARTER RESULTS Operating Earnings Growth in Life Sciences and Clinical Labs
"
10/09/2014
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS STRONG FISCAL FOURTH QUARTER RESULTS Transformative Programs to Heighten Efficiency, Broaden Capabilities Yield Solid Benefits
"
06/12/2013
8-K
Form 8-K - Current report
03/13/2013
8-K
Form 8-K - Current report
12/11/2012
8-K
Form 8-K - Current report
10/15/2012
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM REPORTS FOURTH QUARTER RESULTS AND ANNOUNCES REALIGNMENT PROGRAM EXPECTED TO REDUCE ANNUALIZED COSTS $6 MILLION COMMENCING WITH FISCAL FIRST QUARTER ---
"
06/15/2012
8-K
Form 8-K - Current report
03/14/2012
8-K
Form 8-K - Current report
03/15/2011
8-K
Form 8-K - Current report
12/16/2010
8-K
Quarterly results
Docs:
"
ENZO BIOCHEM ANNOUNCES FIRST QUARTER RESULTS — COMPANY GENERATES POSITIVE EBITDA, IMPROVING $2.9 MILLION SEQUENTIALLY; RECENT ACTIONS TO STREAMLINE OPERATIONS BEGIN TO DRIVE RESULTS
"
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy